Азитромицин – от реалий к перспективе применения

1. Веселов А.В., Козлов Р.С. Азитромицин: современные аспекты клинического применения. Клин. микробиол. и антимикроб. химиотер. 2006; 8 (1): 18–32.
2. Neu H.C. Clinical microbiology of azithromycin. Am J Med 1991; 91 (Suppl. 3A): 12S–18S.
3. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11 (8): 137–52.
4. Betica-Radic Lj, Radonic M. Streptococcus pneumoniae resistance in Dubrovnik 1996. Eur Resp J 1997; 10 (Suppl. 25) Ref. N 1472: 227s228s.
5. Wierzbowski AK, Hoban DJ, Hisanaga T et al. The use of macrolides in treatment of upper respiratory tract infections. Curr Allergy Asthma Rep 2006; 6 (2): 171–81.
6. Garcia-Rey C, Aguilar L, Baquero F et al. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J Clin Microbiol 2002; 40 (8): 2959–63.
7. Cizman M, Beovic B, Seme K et al. Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use. Int J Antimicrob Agents 2006; 28 (6): 537–42.
8. Gagliotti C, Nobilio L, Milandri M, Moro ML. Macrolide prescriptions and erythromycin resistance of Streptococcus pyogenes. Clin Infect Dis 2006; 42 (8): 1153–6.
9. Bergman M, Huikko S, Huovinen P et al. Macrolide and Azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50 (11): 3646–50.
10. Schentag JJ, Klugman KP, Yu VL et al. Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance-a controlled study. Int J Antimicrob Agents 2007; 30 (3): 264–9.
11. Hong KC, Schachter J, Moncada J et al. Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg Infect Dis 2009; 15 (7): 1088–90.
12. Yanagihara K, Izumikawa K, Higa F et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med 2009; 48 (7): 527–35.
13. De Rosa R, Avolio M, Stano P et al. Disappearance of Streptococcus pyogenes macrolides resistance in an area of northeastern Italy: a possible link with rational long-acting macrolide consumption. Infez Med 2009; 17 (2): 82–7.
14. Stout JE, Lin YS, Goetz AM, Muder RR. Controlling Legionella in hospital water systems: experience with the superheat-and-flush method and copper-silver ionization. Infect Control Hosp Epidemiol 1998; 19 (12): 911–4.
15. Синопальников А.И., Чикина С.Ю., Чучалин А.Г. Внебольничная пневмония у взрослых: современные подходы к диагностике, антибактериальной терапии и профилактике (по материалам согласительных рекомендаций Американского общества инфекционистов/Американского торакального общества, 2007). Пульмонология. 2008; 5: 15–50.
16. Blasi F, Tarsia P. Value of short-course antimicrobial therapy in community-acquired pneumonia. Int J Antimicrob Agents 2005; 26 (Suppl. 3): 148–55.
17. Salit IT, Mederski B. Azithromycin for the treatment of acute LRTIs: A multicenter, open-label study. Infect Med 1998; 15 (11): 773–7.
18. Cazzola M, Salzillo A, De Giglio C et al. Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. Respirat Med 2005; 99 (6): 663–9.
19. Milstone A, Patsimas J, Farzan D et al. Prospective observational study of patient-reported outcomes for azithromycin versus usual care in the treatment of bacterial acute exacerbation of chronic bronchitis. Clin Ther 2005; 27 (6): 926–39.
20. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3 (3): 331–50.
21. Hodge S, Hodge G, Jersmann H et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178 (2): 139–48.
22. Wang D, Wang Y, Liu YN. Activity of ciprofloxacin and azithromycin on biofilms produced in vitro by Haemophilus influenza. Chin Med J (Engl) 2009; 122 (11): 1305–10.
23. Zervos M, Breen JD, Jorgense DM, Goodrich JM. Novel, single-dose microsphere formulation of azithromycin versus levofloxacin for the treatment of acute exacerbation of chronic bronchitis. Infect Dis Clin Pract 2005; 13 (3): 115–21.
24. Martinez FJ. Acute exacerbation of chronic bronchitis: expanding short-course therapy. Int J Antimicrob Agents 2005; 26 (Suppl. 3): 156–63.
25. Gerhardt SG, McDyer JF, Girgis RE et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168 (1): 121–5.
26. Khalid M, Al Saghir A, Saleemi S et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005; 25 (3): 490–3.
27. Yates B, Murphy DM, Forrest IA et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172 (6): 772–5.
28. Verleden GM, Dupont LJ, Vanhaecke J et al. Effect of azithromycin on bronchiectasis and pulmonary function in a heart-lung transplant patient with severe chronic allograft dysfunction: a case report. J Heart Lung Transplant 2005; 24 (8): 1155–8.
29. Anwar GA, Bourke SC, Afolabi G et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008; 102 (10): 1494–6.
30. Shinkai M, Park CS, Rubin BK. Immunomodulatory effects of macrolide antibiotics. Clin Pulmon Med 2005; 12 (6): 341–8.
31. Don DM, Goldstein NA, Crockett DM, Ward SD. Antimicrobial therapy for children with adenotonsillar hypertrophy and obstructive sleep apnea: a prospective randomized trial comparing azithromycin vs placebo. Otolaryngol Head Neck Surg 2005; 133 (4): 562–8.
32. Arguedas A, Emparanza P, Schwartz RH et al. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr Infect Dis J 2005; 24 (2): 153–61.
33. Guven M, Bulut Y, Sezer T et al. Bacterial etiology of acute otitis media and clinical efficacy of amoxicillin-clavulanate versus azithromycin. Int J Pediatr Otorhinolaryngol 2006; 70 (5): 915–23.
34. Esposito S, Bosis S, Faelli N et al. Role of atypical bacteria and azithromycin therapy for children with recurrent respiratory tract infections. Pediatr Infect Dis J 2005; 24 (5): 438–44.
35. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. Am J Respir Crit Care Med 2003; 290 (13): 1749–56.
36. Pirzada OM, McGaw J, Taylor CJ, Everard ML. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J Cyst Fibros 2003; 2 (2): 69–71.
37. Clement A, Tamalet A, Le Roux E et al. Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebocontrolled trial. Thorax 2006; 61 (10): 895–902.
38. Wilms EB, Touw DJ, Heijerman HG. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit 2006; 28 (2): 219–25.
39. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007; 19 (1): 83–8.
40. Steinkamp G, Schmitt-Grohe S, Doring G et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 2008; 102 (11): 1643–53.
41. Phaff SJ, Tiddens HA, Verbrugh HA, Ott A. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 2006; 57 (4): 741–6.
42. Tramper-Stranders GA, Wolfs TF, Fleer A et al. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: longterm outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007; 26 (1): 8–12.
43. Dupont HL. Travellers' diarrhoea: contemporary approaches to therapy and prevention. Drugs 2006; 66 (3): 303–14.
44. Saha D, Karim MM, Khan WA et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006; 354 (23): 2452–62.
45. Branden E, Koyi H, Gnarpe J et al. Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection. Scand J Infect Dis 2004; 36 (11–12): 811–6.
46. Хамитов Р.Ф., Пальмова Л.Ю., Новоженов В.Г. Значение антибактериальной терапии при Chlamydophila pneumoniae инфекции у больных бронхиальной астмой. Тер. арх. 2004; 76 (10): 91–4.
47. Johnston SL, Martin RJ. Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis? Am J Respir Crit Care Med 2005; 172 (9): 1078–89.
48. Piacentini GL, Peroni DG, Bodini A et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 2007; 28 (2): 194–8.
49. Strunk RC, Bacharier LB, Phillips BR et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol 2008; 122 (6): 1138–44.
50. Muhlestein JB. Antibiotic treatment of atherosclerosis. Curr Opin Lipidol 2003; 14 (6): 605–14.
51. Grayston JT, Kronmal RA, Jackson LA et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352 (16): 1637–45.
52. Klochkov VA, Dovgalevski PI, Umetski KS et al. Effect of therapy with antibiotics on lipid metabolism and antioxidant reserve of patients with ischemic heart disease during chlamydia pneumonia infection. Kardiologiia 2005; 45 (12): 58–61.
53. Marshall TG, Marshall FE. Antibiotics in sarcoidosis reflections on the first year. JOIMR 2003; 1 (3): 2.
54. English S, Choo-Kang B, Menzies F et al. The effect of long term low dose azithromycin on symptoms and lung function in pulmonary sarcoidosis. Eur Resp J 2008; 32 (Suppl. 52): Ref. 3174.
55. Карпов О.И. Макролиды: новая парадигма фармакодинамика/иммуномодуляция. Практ. мед.: оториноларингология. 2006; 1 (15): 41–3.
56. Shimuzi T, Shimuzi S, Hattori R et al. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Resp Crit Care Med 2003; 168 (5): 581–7.
57. Uriate SM, Molestina RE, Miller RD et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamidia pneumonia infection and tumor necrosis factor-alfa. J Infect Dis 2002; 185: 1631–6.
58. Bakar O, Demircay Z, Yuksel M et al. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol 2007; 32 (2): 197–200.
59. Amsden GW. Anti-inflammatory effects of macrolides an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55 (1): 10–21.
60. Hickey AJ, Lu D, Ashley ED, Stout J. Inhaled azithromycin therapy. J Aerosol Med 2006; 19 (1): 54–60.